|
|||||
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PCRX | SLONIN JONATHAN | Chief Medical Officer | Nov 17 '25 | Sale | 24.09 | 3,960 | 95,396 | 178,367 | Nov 19 04:32 PM |
| PCRX | SLONIN JONATHAN | Officer | Nov 17 '25 | Proposed Sale | 24.09 | 3,960 | 95,396 | Nov 17 10:25 AM | |
| PCRX | SLONIN JONATHAN | Chief Medical Officer | Jan 06 '25 | Sale | 18.40 | 879 | 16,174 | 93,444 | Jan 06 06:23 PM |
| PCRX | SLONIN JONATHAN | Officer | Jan 06 '25 | Proposed Sale | 18.40 | 879 | 16,174 | Jan 06 11:11 AM | |
| PCRX | SLONIN JONATHAN | Chief Medical Officer | Aug 02 '24 | Sale | 20.05 | 945 | 18,947 | 94,307 | Aug 02 06:00 PM |
| PCRX | SLONIN JONATHAN | Officer | Aug 02 '24 | Proposed Sale | 20.05 | 945 | 18,947 | Aug 02 10:09 AM | |
| PCRX | SLONIN JONATHAN | Chief Medical Officer | Jul 02 '24 | Sale | 28.25 | 2,836 | 80,117 | 95,557 | Jul 03 06:52 PM |
| PCRX | SLONIN JONATHAN | Chief Medical Officer | Jun 11 '24 | Sale | 28.57 | 5,012 | 143,193 | 44,569 | Jun 13 06:15 PM |
| PCRX | SLONIN JONATHAN | Chief Clinical Officer | Jun 06 '23 | Sale | 38.99 | 471 | 18,365 | 36,813 | Jun 07 09:32 PM |
| PCRX | SLONIN JONATHAN | Chief Clinical Officer | Jun 07 '23 | Sale | 37.87 | 490 | 18,554 | 36,323 | Jun 07 09:32 PM |
| PCRX | SLONIN JONATHAN | Chief Clinical Officer | Aug 03 '22 | Sale | 55.70 | 308 | 17,156 | 37,079 | Aug 05 04:04 PM |
| PCRX | SLONIN JONATHAN | Chief Clinical Officer | Jul 05 '22 | Sale | 57.19 | 924 | 52,842 | 37,387 | Jul 07 07:04 PM |
| PCRX | SLONIN JONATHAN | Chief Clinical Officer | Jun 06 '22 | Sale | 61.37 | 362 | 22,217 | 28,197 | Jun 08 07:45 PM |
| PCRX | SLONIN JONATHAN | Chief Clinical Officer | May 23 '22 | Option Exercise | 52.37 | 2,000 | 104,740 | 28,559 | May 25 04:16 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite